Scinai Logo.jpg
BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
06 sept. 2023 06h00 HE | BiondVax Pharmaceuticals Ltd.
JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company, is pleased to announce today a change of its corporate name to...
ibn-iw-globe-2.png
IBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutes
03 mars 2023 14h07 HE | InvestorBrandNetwork (IBN)
LOS ANGELES, March 03, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN, a multifaceted financial news and publishing company for private and public entities, today announces that Amir Reichman, CEO...
ibn-iw-globe-2.png
IBN Announces Latest Episode of The Stock2Me Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.
13 déc. 2022 08h17 HE | InvestorBrandNetwork (IBN)
LOS ANGELES, Dec. 13, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to...
BiondVax LOGO.png
BiondVax Regains Nasdaq Compliance
12 déc. 2022 07h06 HE | BiondVax Pharmaceuticals Ltd.
JERUSALEM, Dec. 12, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and...
BiondVax LOGO.png
IBN (InvestorBrandNetwork) Coverage Initiated for BiondVax Pharmaceuticals Ltd.
06 déc. 2022 08h30 HE | BiondVax Pharmaceuticals Ltd.
LOS ANGELES, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing...
Professor Dr. med. Matthias Dobbelstein_cropped
Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board
06 déc. 2022 07h30 HE | BiondVax Pharmaceuticals Ltd.
Jerusalem, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing...
BiondVax LOGO.png
BiondVax announces Third Quarter 2022 Financial Results and Provides Business Update
30 nov. 2022 09h15 HE | BiondVax Pharmaceuticals Ltd.
JERUSALEM, Nov. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing, and commercializing innovative...
BiondVax LOGO.png
BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy
29 nov. 2022 07h00 HE | BiondVax Pharmaceuticals Ltd.
Hamsters infected with SARS-COV-2 and then treated with inhaled anti-COVID-19 NanoAbs demonstrated significantly less severe illness and faster recovery in comparison to infected hamsters treated with...
BiondVax LOGO.png
BiondVax Congratulates Dirk Görlich on $1.4 million WLA Prize in Life Sciences
15 nov. 2022 08h33 HE | BiondVax Pharmaceuticals Ltd.
JERUSALEM, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and...
BiondVax LOGO.png
BiondVax Announces Plan to Implement ADS Ratio Change
10 nov. 2022 16h00 HE | BiondVax Pharmaceuticals Ltd.
JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and...